Obesity is a major risk factor for Type 2 diabetes, heart disease, stroke, sleep apnea, liver disease, and certain cancers.
It’s estimated that around 40% of the adult non-diabetic population in the U.S. is obese.
Over the past few years, GLP‑1 medications have become mainstream for the treatment of both obesity and Type 2 diabetes. GLP-1 receptor agonists – such as Ozempic, Wegovy, Mounjaro and Zepbound – mimic the body’s GLP-1 hormone which helps manage blood sugar levels, suppresses appetite and slows the process of food leaving the stomach.
GLP-1 agonists have been shown to reduce effects of metabolic risk factors including obesity, diabetes and in atherosclerotic cardiovascular disease. However, there is also a high incidence of regaining weight loss after stopping the GLP-1, in some cases with weight returning to baseline levels within 1 to 2 years. Ongoing lifestyle change is key for long term success beyond treatment.
When it comes to underwriting, here are a few things carriers look for in assessing the use of GLP-1 medications:
- Indication – What is the medication treating? Weight loss, diabetes, or both
- Weight loss history over a period of one year – What is the current height/weight and what is the total amount of weight loss in the prior year? To account for stability risk, carriers will underwrite based on an adjusted weight that includes adding back half of the weight lost within the prior 12 months
- Comorbidities – Are there any diagnoses for co-morbid conditions such as Type 2 diabetes, cardiovascular disease, sleep apnea and hypertension? Additional ratings may apply if comorbidities are present
- Healthy lifestyle habits – A healthy lifestyle can help with a more favorable underwriting assessment. These include diet, exercise habits, and a lifelong nonsmoker
Contact our Underwriting Team of experts to help get the best possible offers with your GLP-1 scenarios.